Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (34908) 34908
Newsletter (3737) 3737
Publication (2919) 2919
Book Review (611) 611
Book Chapter (259) 259
Newspaper Article (89) 89
Magazine Article (73) 73
Dissertation (70) 70
Conference Proceeding (64) 64
Book / eBook (32) 32
Trade Publication Article (21) 21
Reference (11) 11
Web Resource (8) 8
Paper (6) 6
Data Set (4) 4
Transcript (4) 4
Journal / eJournal (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (19577) 19577
index medicus (14636) 14636
male (13794) 13794
angiotensin (12078) 12078
animals (11628) 11628
hypertension (9895) 9895
female (9388) 9388
angiotensin-converting enzyme inhibitors - therapeutic use (6553) 6553
middle aged (6480) 6480
rats (6306) 6306
hypertension - drug therapy (5759) 5759
aged (5624) 5624
cardiac & cardiovascular systems (4876) 4876
peripheral vascular disease (4774) 4774
pharmacology & pharmacy (4559) 4559
research (4476) 4476
renin-angiotensin system (4472) 4472
blood pressure - drug effects (4236) 4236
angiotensin ii type 1 receptor blockers - therapeutic use (4127) 4127
antihypertensive agents - therapeutic use (4039) 4039
angiotensin ii (3940) 3940
blood-pressure (3820) 3820
adult (3648) 3648
heart failure (3636) 3636
angiotensin-ii (3596) 3596
risk factors (3566) 3566
blood pressure (3525) 3525
treatment outcome (3419) 3419
renin-angiotensin system - drug effects (3088) 3088
angiotensin ii type 1 receptor blockers - pharmacology (3074) 3074
mortality (3032) 3032
hypertension - physiopathology (2859) 2859
urology & nephrology (2723) 2723
drug therapy (2674) 2674
analysis (2622) 2622
diabetes (2608) 2608
drug therapy, combination (2603) 2603
oxidative stress (2506) 2506
mice (2464) 2464
enzymes (2366) 2366
physiology (2347) 2347
care and treatment (2338) 2338
ace inhibitors (2310) 2310
losartan (2278) 2278
angiotensin receptor antagonists (2221) 2221
medicine & public health (2150) 2150
angiotensin-converting enzyme inhibitors - pharmacology (2139) 2139
tetrazoles - therapeutic use (2130) 2130
heart failure - drug therapy (2126) 2126
rats, sprague-dawley (2089) 2089
expression (2075) 2075
angiotensin ii - pharmacology (2047) 2047
medicine, general & internal (1977) 1977
adrenergic beta-antagonists - therapeutic use (1965) 1965
renin-angiotensin system - physiology (1942) 1942
health aspects (1932) 1932
time factors (1875) 1875
valsartan (1852) 1852
physiological aspects (1833) 1833
tetrazoles - pharmacology (1828) 1828
heart-failure (1760) 1760
cardiology (1752) 1752
reports (1725) 1725
dose-response relationship, drug (1720) 1720
antihypertensive agents - pharmacology (1717) 1717
hypertension - complications (1714) 1714
disease models, animal (1674) 1674
internal medicine (1671) 1671
endocrinology & metabolism (1659) 1659
enzyme inhibitors (1620) 1620
renin (1607) 1607
aged, 80 and over (1604) 1604
losartan - pharmacology (1589) 1589
angiotensin receptor antagonists - therapeutic use (1580) 1580
myocardial-infarction (1562) 1562
medical research (1557) 1557
aldosterone (1550) 1550
cardiovascular (1536) 1536
rats, wistar (1522) 1522
prevention (1506) 1506
inflammation (1504) 1504
medicine (1502) 1502
risk (1500) 1500
angiotensin ii - metabolism (1488) 1488
calcium channel blockers - therapeutic use (1476) 1476
disease (1463) 1463
angiotensin-converting enzyme inhibitors (1433) 1433
article (1431) 1431
system (1387) 1387
heart (1376) 1376
abridged index medicus (1335) 1335
rodents (1321) 1321
fibrosis (1317) 1317
receptor, angiotensin, type 1 - metabolism (1311) 1311
benzimidazoles - therapeutic use (1305) 1305
medicine, experimental (1303) 1303
medicine, research & experimental (1299) 1299
angiotensin-converting enzyme (1282) 1282
therapy (1278) 1278
cardiovascular disease (1270) 1270
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (37542) 37542
Japanese (422) 422
German (246) 246
Russian (170) 170
Chinese (142) 142
Spanish (126) 126
French (112) 112
Korean (68) 68
Italian (54) 54
Hungarian (33) 33
Portuguese (33) 33
Polish (31) 31
Czech (26) 26
Danish (21) 21
Dutch (12) 12
Swedish (12) 12
Turkish (10) 10
Norwegian (9) 9
Croatian (8) 8
Ukrainian (8) 8
Finnish (4) 4
Hebrew (4) 4
Persian (4) 4
Serbian (4) 4
Slovak (4) 4
Lithuanian (3) 3
Romanian (2) 2
Bosnian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial
by Sandset, Else Charlotte, MD and Bath, Philip MW, Prof and Boysen, Gudrun, Prof and Jatuzis, Dalius, MD and Kõrv, Janika, MD and Lüders, Stephan, MD and Murray, Gordon D, Prof and Richter, Przemyslaw S, MD and Roine, Risto O, Prof and Terént, Andreas, Prof and Thijs, Vincent, MD and Berge, Eivind, Dr and SCAST Study Grp and SCAST Study Group and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Uppsala universitet and Institutionen för medicinska vetenskaper
Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9767, pp. 741 - 750
Summary Background Raised blood pressure is common in acute stroke, and is associated with an increased risk of poor outcomes. We aimed to examine whether... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | DESIGN | MANAGEMENT | ACUTE ISCHEMIC STROKE | INTRAVENOUS NIMODIPINE | GUIDELINES | CEREBRAL-HEMORRHAGE TRIAL | OUTCOMES | BLOOD-PRESSURE REDUCTION | HYPERTENSION | INTERVENTION | Meta-Analysis as Topic | Angiotensin II Type 1 Receptor Blockers - adverse effects | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Stroke - physiopathology | Benzimidazoles - administration & dosage | Tetrazoles - administration & dosage | Treatment Failure | Aged, 80 and over | Female | Blood Pressure - drug effects | Benzimidazoles - adverse effects | Odds Ratio | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Brain Ischemia - complications | Double-Blind Method | Drug Administration Schedule | Europe | Stroke - drug therapy | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | Regression Analysis | Stroke - etiology | Aged | Tetrazoles - adverse effects | Cerebral Hemorrhage - complications | Hypertension | Stroke (Disease) | Complications and side effects | Candesartan | Research | Drug therapy | Health aspects | Studies | Stroke | Blood pressure | Clinical medicine | blood pressure | Hospitals | stroke | Mortality | myocardial infarction | composite materials | Medical and Health Sciences | MEDICINE | Medicin och hälsovetenskap | MEDICIN
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Feasibility of Treating Prehypertension with an Angiotensin-Receptor Blocker
by Julius, Stevo and Nesbitt, Shawna D and Egan, Brent M and Weber, Michael A and Michelson, Eric L and Kaciroti, Niko and Black, Henry R and Grimm, Richard H and Messerli, Franz H and Oparil, Suzanne and Schork, M. Anthony and TROPHY Study Investigators and Trial of Preventing Hypertension (TROPHY) Study Investigators
The New England Journal of Medicine, ISSN 0028-4793, 04/2006, Volume 354, Issue 16, pp. 1685 - 1697
Persons with prehypertension (formerly, “borderline hypertension”) were randomly assigned in a blinded fashion to receive two years of candesartan or placebo,... 
UNITED-STATES | SPONTANEOUSLY HYPERTENSIVE RATS | MEDICINE, GENERAL & INTERNAL | NORMAL BLOOD-PRESSURE | METABOLIC CHARACTERISTICS | RISK-FACTORS | CONVERTING-ENZYME-INHIBITOR | CLINICAL-TRIAL | BORDERLINE HYPERTENSION | PREVENTION | PROGRESSION | Antihypertensive Agents - pharmacology | Angiotensin II Type 1 Receptor Blockers - adverse effects | Tetrazoles - pharmacology | Dyslipidemias - complications | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Biphenyl Compounds - adverse effects | Male | Angiotensin II Type 1 Receptor Blockers - pharmacology | Biphenyl Compounds - therapeutic use | Feasibility Studies | Incidence | Biphenyl Compounds - pharmacology | Hypertension - prevention & control | Adult | Female | Blood Pressure - drug effects | Hypertension - epidemiology | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Double-Blind Method | Obesity - complications | Logistic Models | Obesity - physiopathology | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Benzimidazoles - pharmacology | Tetrazoles - therapeutic use | Aged | Tetrazoles - adverse effects | Dyslipidemias - physiopathology | Hypertension | Dosage and administration | Research | Drug therapy | Candesartan | Automation | Blood pressure | Lifestyles
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Combined Effect of Angiotensin II Receptor Blocker and Either a Calcium Channel Blocker or Diuretic on Day-by-Day Variability of Home Blood Pressure: The Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study
by Matsui, Yoshio and OʼRourke, Michael F and Hoshide, Satoshi and Ishikawa, Joji and Shimada, Kazuyuki and Kario, Kazuomi
Hypertension, ISSN 0194-911X, 06/2012, Volume 59, Issue 6, pp. 1132 - 1138
Day-by-day home blood pressure (BP) variability (BPV) was reported to be associated with increased cardiovascular risk. We aimed to test the hypothesis that... 
Home blood pressure | Pulse wave velocity | Day-by-day home blood pressure variability | Angiotensin II receptor blocker | Thiazide diuretic | Calcium channel blocker | thiazide diuretic | PREDICTOR | BAROREFLEX SENSITIVITY | OHASAMA | day-by-day home blood pressure variability | pulse wave velocity | HYPERTENSIVE PATIENTS | AMLODIPINE | INFARCTION | calcium channel blocker | HIGH-RISK | angiotensin II receptor blocker | DISEASE | PERIPHERAL VASCULAR DISEASE | HEART-RATE | home blood pressure | VISIT-TO-VISIT | Multivariate Analysis | Prospective Studies | Drug Administration Schedule | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Calcium Channel Blockers - therapeutic use | Hypertension - drug therapy | Male | Treatment Outcome | Azetidinecarboxylic Acid - analogs & derivatives | Hypertension - physiopathology | Dihydropyridines - therapeutic use | Azetidinecarboxylic Acid - therapeutic use | Diuretics - therapeutic use | Female | Tetrazoles - therapeutic use | Aged | Blood Pressure - drug effects | Blood Pressure Monitoring, Ambulatory - methods | Imidazoles - therapeutic use | Drug Therapy, Combination | Hydrochlorothiazide - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Angiotensin II receptor blockers
: a comparative effectiveness review
by Pohar, Ron and Farrah, Kelly and Canadian Electronic Library (Firm) and Canadian Agency for Drugs and Technologies in Health. Health Technology Inquiry Service
2008, Health technology inquiry service (HTIS)
Cardiovascular system | Prevention | Cardiovascular Diseases | Angiotensin Receptor Antagonists | Antagonists | prevention & control | Angiotensin II | Therapeutic use | Diseases
Web Resource
Details down arrow
5. Full Text Neuroprotective Effects of Angiotensin Receptor Blockers
by Villapol, Sonia and Saavedra, Juan M
American Journal of Hypertension, ISSN 0895-7061, 3/2015, Volume 28, Issue 3, pp. 289 - 299
Angiotensin II receptor blockers (ARBs, collectively called sartans) are widely used compounds therapeutically effective in cardiovascular disorders, renal... 
Hypertension | Neuroprotection | Parkinson's disease | Traumatic brain injury | Angiotensin receptor blockers | Neuronal injury | Renin-angiotensin system | Neurodegenerative disorders | Sartans | Brain inflammation | Blood pressure | Angiotensin II | Alzheimer's disease | blood pressure | angiotensin receptor blockers | SPONTANEOUSLY HYPERTENSIVE-RATS | neuronal injury | II TYPE-1 RECEPTOR | ALZHEIMERS-DISEASE | traumatic brain injury | INNATE IMMUNE-RESPONSE | neurodegenerative disorders | PPAR-GAMMA ACTIVATION | BLOOD-BRAIN-BARRIER | brain inflammation | COGNITIVE DECLINE | VASCULAR DEMENTIA | AT RECEPTORS | angiotensin II | neuroprotection | sartans | PERIPHERAL VASCULAR DISEASE | hypertension | renin-angiotensin system | PARKINSONS-DISEASE | Neuroprotective Agents - therapeutic use | Brain Diseases - drug therapy | Animals | Neuroprotective Agents - pharmacology | Humans | Angiotensin Receptor Antagonists - pharmacology | Renin-Angiotensin System - drug effects | Angiotensin Receptor Antagonists - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Fimasartan: A New Angiotensin Receptor Blocker
by Lee, Hae-Young and Oh, Byung-Hee
Drugs, ISSN 0012-6667, 7/2016, Volume 76, Issue 10, pp. 1015 - 1022
Fimasartan is the ninth, and most recent, angiotensin II receptor antagonist approved as an antihypertensive agent. Fimasartan, a pyrimidin-4(3H)-one... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | LOSARTAN | PHARMACOKINETICS | EFFICACY | ABSOLUTE BIOAVAILABILITY | ANTAGONIST FIMASARTAN | PARALLEL-GROUP | DOUBLE-BLIND | KOREAN PATIENTS | PHARMACOLOGY & PHARMACY | OPEN-LABEL | PHARMACODYNAMICS | TOXICOLOGY | Angiotensin II Type 2 Receptor Blockers - pharmacokinetics | Humans | Antihypertensive Agents - administration & dosage | Biphenyl Compounds - adverse effects | Hypertension - drug therapy | Biphenyl Compounds - therapeutic use | Dose-Response Relationship, Drug | Tetrazoles - administration & dosage | Observational Studies as Topic | Molecular Structure | Drug Evaluation, Preclinical | Drug Therapy, Combination | Biphenyl Compounds - pharmacokinetics | Pyrimidines - administration & dosage | Treatment Outcome | Angiotensin II Type 2 Receptor Blockers - adverse effects | Clinical Trials as Topic | Antihypertensive Agents - pharmacokinetics | Antihypertensive Agents - therapeutic use | Angiotensin II Type 2 Receptor Blockers - therapeutic use | Antihypertensive Agents - adverse effects | Hypertension - metabolism | Animals | Pyrimidines - therapeutic use | Biphenyl Compounds - administration & dosage | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Angiotensin II Type 2 Receptor Blockers - administration & dosage | Tetrazoles - therapeutic use | Tetrazoles - adverse effects | Tetrazoles - pharmacokinetics | Hypertension | Stroke (Disease) | Prevention | Care and treatment | Usage | Angiotensin II receptor blockers | Clinical trials | Dosage and administration | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Comparative Effects of an Angiotensin II Receptor Blocker (ARB)/Diuretic vs. ARB/Calcium-Channel Blocker Combination on Uncontrolled Nocturnal Hypertension Evaluated by Information and Communication Technology-Based Nocturnal Home Blood Pressure Monitoring　― The NOCTURNE Study
by Kario, Kazuomi and Tomitani, Naoko and Kanegae, Hiroshi and Ishii, Hajime and Uchiyama, Kazuaki and Yamagiwa, Kayo and Shiraiwa, Toshihiko and Katsuya, Tomohiro and Yoshida, Tetsuro and Kanda, Kiyomi and Hasegawa, Shinji and Hoshide, Satoshi
Circulation Journal, ISSN 1346-9843, 2017, Volume 81, Issue 7, pp. 948 - 957
Background:Nocturnal blood pressure (BP) is an independent risk factor of cardiovascular events. The NOCTURNE study, a multicenter, randomized controlled trial... 
Diuretics | Nocturnal blood pressure | Calcium-channel blockers (CCBs) | Information and communication technology (ICT)-based home blood pressure monitoring | Angiotensin II receptor blockers (ARBs) | DIPPER | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | CIRCADIAN-RHYTHM | ORGAN DAMAGE | ASSOCIATION | NONDIPPER | Diuretics - administration & dosage | Trichlormethiazide - administration & dosage | Humans | Middle Aged | Hypertension - drug therapy | Male | Blood Pressure Monitoring, Ambulatory - instrumentation | Hypertension - physiopathology | Tetrazoles - administration & dosage | Biphenyl Compounds - administration & dosage | Calcium Channel Blockers - administration & dosage | Female | Aged | Blood Pressure Monitoring, Ambulatory - methods | Amlodipine - administration & dosage | Angiotensin Receptor Antagonists - administration & dosage | Communication
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Angiotensin-Converting Enzyme Inhibitor, Angiotensin Receptor Blocker Use, and Mortality in Patients With Chronic Kidney Disease
by Molnar, Miklos Z., MD, PhD and Kalantar-Zadeh, Kamyar, MD, MPH, PhD and Lott, Evan H and Lu, Jun Ling, MD and Malakauskas, Sandra M., MD, PhD and Ma, Jennie Z., PhD and Quarles, Darryl L., MD and Kovesdy, Csaba P., MD
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2014, Volume 63, Issue 7, pp. 650 - 658
Objectives The study objective was to assess the association between angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) use and... 
Cardiovascular | Internal Medicine | mortality | angiotensin-converting enzyme inhibitors | chronic kidney disease | angiotensin receptor blockers | SURVIVAL | SYSTEM INHIBITORS | CARDIAC & CARDIOVASCULAR SYSTEMS | PROPENSITY SCORE ANALYSIS | MYOCARDIAL-INFARCTION | ACE-INHIBITION | DIABETIC-NEPHROPATHY | CHRONIC RENAL-INSUFFICIENCY | HYPERTENSIVE PATIENTS | HEMODIALYSIS-PATIENTS | CONGESTIVE-HEART-FAILURE | Receptors, Angiotensin - metabolism | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Male | Renal Insufficiency, Chronic - drug therapy | Renal Insufficiency, Chronic - metabolism | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Aged, 80 and over | Renal Insufficiency, Chronic - mortality | Female | Aged | Cohort Studies | Hypertension | Sects | Chronic kidney failure | Patient outcomes | Mortality | Angiotensin | ACE inhibitors | Medical research | Analysis | Medicine, Experimental | Angiotensin-converting enzyme inhibitors | Laboratories | Cardiovascular disease | Subgroups | Confidence intervals | Enzyme inhibitors | Motivation | Peptidyl-dipeptidase A | Heart failure | Urine | Enzymes | Statistical analysis | Kidneys | Comorbidity | Diabetes mellitus | Calendars | Regression analysis | Patients | Inhibitors | Statistical models | Converting | Pharmacy | Coronary vessels | Diabetes | Kidney diseases | Potassium
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Azilsartan Medoxomil: A New Angiotensin Receptor Blocker
by Zaiken, Kathy, PharmD and Cheng, Judy W.M., PharmD, MPH, FCCP, BCPS
Clinical Therapeutics, ISSN 0149-2918, 2011, Volume 33, Issue 11, pp. 1577 - 1589
Abstract Background Azilsartan medoxomil is an angiotensin receptor blocker, approved on February 25, 2011 by the US Food and Drug Administration (FDA) for... 
Internal Medicine | Medical Education | hypertension | angiotensin receptor blocker | azilsartan medoxomil | Hypertension | Azilsartan medoxomil | Angiotensin receptor blocker | PHARMACOLOGY & PHARMACY | CONVERTING ENZYME-INHIBITORS | FAILURE | BLOOD-PRESSURE | Antihypertensive Agents - pharmacology | Humans | Angiotensin Receptor Antagonists - pharmacology | Hypertension - drug therapy | Clinical Trials as Topic | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Oxadiazoles - therapeutic use | Oxadiazoles - adverse effects | Oxadiazoles - pharmacology | Cost-Benefit Analysis | Benzimidazoles - pharmacology | Benzimidazoles - adverse effects | Angiotensin Receptor Antagonists - therapeutic use | Angiotensin Receptor Antagonists - adverse effects | Benzimidazoles - therapeutic use | Angiotensin | Studies | Clinical trials | Cardiovascular disease | Drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Ranolazine, ACE Inhibitors, and Angiotensin Receptor Blockers
by Marciniak, Thomas A and Serebruany, Victor
The American journal of medicine, ISSN 0002-9343, 03/2019
Ranolazine is an anti-angina agent with many metabolites creating the potential for off-target effects. FDA reviews sometimes contain clinically relevant data... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
by Cohn, Jay N and Tognoni, Gianni and Valsartan Heart Failure Trial Inve and Valsartan Heart Failure Trial Investigators
The New England Journal of Medicine, ISSN 0028-4793, 12/2001, Volume 345, Issue 23, pp. 1667 - 1675
Angiotensin II may contribute to the progression of heart failure. In this trial, valsartan, an angiotensin-receptor blocker, reduced the need for... 
MORTALITY | MEDICINE, GENERAL & INTERNAL | MORBIDITY | RATIONALE | DYSFUNCTION | LEFT-VENTRICULAR HYPERTROPHY | ENALAPRIL | AT1 | Double-Blind Method | Valsartan | Angiotensin Receptor Antagonists | Humans | Middle Aged | Valine - analogs & derivatives | Heart Failure - physiopathology | Probability | Stroke Volume - drug effects | Male | Hospitalization | Heart Failure - drug therapy | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Survival Analysis | Quality of Life | Female | Tetrazoles - therapeutic use | Valine - therapeutic use | Drug Therapy, Combination | Chronic Disease | Adrenergic beta-Antagonists - therapeutic use | Heart Failure - mortality | Heart failure | Evaluation | Drug therapy | Angiotensin II receptor blockers | Drug dosages | Mortality | Quality of life
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies
by Ojima, Mami and Igata, Hideki and Tanaka, Masayuki and Sakamoto, Hiroki and Kuroita, Takanobu and Kohara, Yasuhisa and Kubo, Keiji and Fuse, Hiromitsu and Imura, Yoshimi and Kusumoto, Keiji and Nagaya, Hideaki
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 03/2011, Volume 336, Issue 3, pp. 801 - 808
The angiotensin II (AII) antagonistic action of azilsartan (AZL)... 
POTENT | ACTIVATION | MANAGEMENT | AT RECEPTOR | CV-11974 | PHARMACOLOGY | INVERSE AGONIST | PHARMACOLOGY & PHARMACY | ESSENTIAL-HYPERTENSION | CANDESARTAN CILEXETIL | VALSARTAN | Rabbits | Angiotensin II Type 1 Receptor Blockers - chemistry | Receptor, Angiotensin, Type 1 - physiology | Humans | Aorta, Thoracic - metabolism | Cercopithecus aethiops | Male | Benzimidazoles - chemistry | Angiotensin II Type 1 Receptor Blockers - pharmacology | Angiotensin II Type 1 Receptor Blockers - metabolism | Dose-Response Relationship, Drug | Animals | Oxadiazoles - pharmacology | Benzimidazoles - metabolism | Receptor, Angiotensin, Type 1 - metabolism | Benzimidazoles - pharmacology | Aorta, Thoracic - drug effects | Oxadiazoles - chemistry | COS Cells | Oxadiazoles - metabolism | Protein Binding - physiology
Journal Article
Details down arrow